cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk shares plunge after drug trial disappoints Novo Nordisk's CagriSema outperforms Ozempic – cagrisema semaglutide cagrilintide phase 3

Rayner CK, et al

As reports of sudden vision loss accumulated, researchers and clinicians began to question whether semaglutide could increase the risk of optic nerve injury in certain patients

The consequences are significant: accelerated muscle loss, a soft flabby appearance despite weight loss, reduced metabolic rate, weakened immune function, hair loss, and poor recovery from exercise

It may be useful in certain medical situations, especially confirmed carnitine deficiency, but routine supplementation is not necessary for most healthy people

However, compared to that in non-malignant tissues, the expression level of GPx1 in tumor tissues was significantly decreased by 7.4% [83]